Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics (NQ: CLDX )

37.33 +2.80 (+8.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 582,593
Open 34.88
Bid (Size) 37.32 (5)
Ask (Size) 37.33 (8)
Prev. Close 34.53
Today's Range 34.31 - 37.98
52wk Range 19.85 - 57.20
Shares Outstanding 46,772,351
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
 
Via Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday. 
Via Benzinga

Performance

YTD
-4.72%
-4.72%
1 Month
+38.62%
+38.62%
3 Month
+24.47%
+24.47%
6 Month
+17.95%
+17.95%
1 Year
-17.34%
-17.34%

More News

Read More
Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study
Via Benzinga
Earnings Scheduled For February 28, 2022
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here's What You Need To Know
Via Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
Via Investor's Business Daily
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Via Benzinga
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
Via InvestorPlace
Celldex Therapeutics: Q4 Earnings Insights
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Bear Market Bets In Biotech
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
The Secret To Successful Investing In Biotech
Via Talk Markets
77 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 17, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
Via Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.